Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MCLA-128 combinations in metastatic breast cancer
NL-OMON48717Phase 2Active, not recruiting
- Sponsor
- Merus
- Start
- Jul 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of zenocutuzumab in breast cancer (3 cohorts), sponsored by Merus. Primary endpoint: Clinical benefit rate at 24 weeks. Started Jul 2019; status: active, not recruiting.
02
Drugs
zenocutuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON48717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48717.